Laronidase: profile and news

BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I ... - Yahoo! News (press release)

BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased 36 percent to ... - PR Newswire (press release),

Other information

Indication
For treatment of mucopolysaccharidosis

Pharmacology
Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.

Mechanism Of Action
Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.

Drug Category
Enzyme replacement; enzymes (44:00.00)

Brand Names/Synonyms
Alpha-L-iduronidase precursor; Aldurazyme (Biomarin Pharmaceuticals)

Dosage Forms
SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human alpha-L-iduronidase

Chemical Formula
C3160H4848N898O881S12

Half Life
1.5-3.6 hrs

Drug Type
Approved Drug

# Accession No
BIOD00008

CAS Registry Number
50378-38-2; 210589-09-6